


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-37 (cancelled)

Claim 38 (previously presented): A valency platform molecule having the structure:



or an aminooxy protected form thereof,

wherein n is about 481.

Claims 39-45 (cancelled)

Claim 46 (currently amended): A conjugate of a molecule of claim 38 and one or more biologically active molecules, wherein the conjugate optionally comprises one or more linker moiety.

Claims 47-53 (cancelled)

Claim 54 (previously presented): The conjugate of claim 46 wherein the biologically active molecules are selected from the group consisting of: oligonucleotides, peptides, polypeptides, proteins, antibodies, saccharides, polysaccharides, epitopes, mimotopes, enzymes, hormones, drugs, nucleic acids, lipids, fatty acids, and mixtures thereof.


Claim 55 (previously presented): The conjugate of claim 54, wherein the biologically active molecules comprise a domain 1 polypeptide of β 2GPI.

Claim 56 (previously presented): The conjugate of claim 55, wherein the polypeptide lacks a T cell epitope.

Claim 57 (previously presented): The conjugate of claim 55, wherein the conjugate comprises a linker that attaches the domain 1 polypeptide of β 2GPI to the valency platform molecule.

Claims 58-65 (cancelled)

Claim 66 (previously presented): A valency platform molecule having the structure:



or an aminooxy protected form thereof,

wherein the $(CH_2CH_2O)_n$ moiety has a molecular weight of about 20K g/mol.


Claim 67 (currently amended): A conjugate of a molecule of claim 66 and one or more biologically active molecules, wherein the conjugate optionally comprises one or more linker moiety.

Claim 68 (previously presented): The conjugate of claim 67, wherein the biologically active molecules are selected from the group consisting of oligonucleotides, peptides, polypeptides, proteins, antibodies, saccharides, polysaccharides, epitopes, mimotopes, enzymes, hormones, drugs, nucleic acids, lipids, fatty acids, and mixtures thereof.

Claim 69 (previously presented): The conjugate of claim 68, wherein the biologically active molecules comprise a domain 1 polypeptide of β 2GPI.

Claim 71 (previously presented): The conjugate of claim 69, wherein the conjugate comprises a linker that attaches the domain 1 polypeptide of $\beta 2\text{GPI}$ to the valency platform molecule.

Claim 82 (previously presented): A valency platform molecule having the formula:



wherein n is about 200 to about 500.

Claim 84 (previously presented): The conjugate of claim 83, wherein the biologically active molecules are selected from the group consisting of oligonucleotides, peptides, polypeptides, proteins, antibodies, saccharides, polysaccharides, epitopes, mimotopes, enzymes, hormones, drugs, nucleic acids, lipids, fatty acids, and mixtures thereof.

Claim 85 (previously presented): The conjugate of claim 84, wherein the biologically active molecules comprise a domain 1 polypeptide of β 2GPI.

Claim 86 (previously presented): The conjugate of claim 85, wherein the polypeptide lacks a T cell epitope.

Claim 87 (previously presented): The conjugate of claim 85, wherein the conjugate comprises a linker that attaches the domain 1 polypeptide of β 2GPI to the valency platform molecule.

Claim 88 (cancelled)

Claim 89 (currently amended): A method of making the conjugate according to claim 46, comprising covalently bonding biologically active molecules to ~~a valency platform molecule~~ said valency platform molecule such that an oxime bond, or modified form thereof, is formed.

Claim 90 (currently amended): The method of claim 89, wherein the bond is the modified oxime bond and the modified oxime bond is a reduced or alkylated oxime bond.

Claim 91 (currently amended): The method of claim 89, wherein ~~the valency platform molecule comprises an aminooxy group and~~ the biologically active molecules are bound to the valency platform molecule via a linker group such that an oxime bond, or modified form thereof, is formed upon bonding the linker group to the valency platform molecule.

Claim 92 (previously presented): The method of claim 89, wherein the biologically active molecules comprise a carbonyl group of an aldehyde or ketone moiety.

Claim 93 (previously presented): The method of claim 92, wherein the biologically active molecules comprise a polypeptide; and, wherein the method comprises modifying the polypeptide prior to bonding with an aminooxy group on the valency platform molecule, such that the polypeptide comprises a terminal aldehyde group.

Claims 94-107 (cancelled)

Claim 108 (previously presented): The conjugate of claim 46, wherein the conjugate comprises one or more bivalent linker molecules that link a biologically active molecule to the valency platform molecule such that a linkage bond is formed between the bivalent linker molecule and the valency platform molecule.

Claim 109 (previously presented): The conjugate of claim 46 wherein the biologically active molecule is a polypeptide comprising a terminal glyoxyl group that reacts with an aminooxy group on the valency platform molecule to form an oxime linkage.

Claim 110 (currently amended): The conjugate of claim 108 ~~109~~, wherein the linkage bond is formed by reacting the valency platform molecule with the bivalent linker molecule, wherein the bivalent linker molecule comprises a carbonyl containing functional moiety.

Claims 111-118 (cancelled)

Claim 119 (previously presented): A pharmaceutical composition comprising the conjugate of claim 46 and a pharmaceutically acceptable carrier.

Claims 120-123 (cancelled)

Claim 124 (previously presented): A composition comprising two or more valency platform molecules according to claim 38 wherein the valency platform molecules have a polydispersity less than about 1.2.

Claim 125 (cancelled)

Claim 126 (previously presented): The conjugate of claim 54 wherein the biologically active molecules comprise a polypeptide.

Claim 127 (previously presented): The conjugate of claim 54 wherein the biologically active molecules comprise a nucleic acid.

Claim 128 (previously presented): The conjugate of claim 54 wherein the biologically active molecules comprise an oligonucleotide.

Claims 129-130 (cancelled)

Claim 131 (currently amended): A method of making the conjugate according to claim 67, comprising: covalently bonding biologically active molecules to ~~a valency platform molecule~~ said valency platform molecule such that an oxime bond, or modified form thereof, is formed.

Claim 132 (currently amended): The method of claim 131, wherein the bond is the modified oxime bond and the modified oxime bond is a reduced or alkylated oxime bond.

Claim 133 (currently amended): The method of claim 131, wherein ~~the valency platform molecule comprises an aminooxy group and~~ the biologically active molecules are bound to the valency platform molecule via a linker group such that an oxime bond, or modified form thereof, is formed upon bonding the linker group to the valency platform molecule.

Claim 134 (previously presented): The method of claim 131 wherein the biologically active molecules comprise a carbonyl group of an aldehyde or ketone moiety.

Claim 135 (previously presented): The method of claim 134, wherein the biologically active molecules comprise a polypeptide; and, wherein the method comprises modifying the polypeptide prior to bonding with an aminooxy group on the valency platform molecule, such that the polypeptide comprises a terminal aldehyde group.

Claim 136 (previously presented): A method of making the conjugate according to claim 83, comprising: covalently bonding biologically active molecules to a valency platform molecule such that an oxime bond, or modified form thereof, is formed.

Claim 137 (currently amended): The method of claim 136, wherein the bond is the modified oxime bond and the modified oxime bond is a reduced or alkylated oxime bond.

Claim 138 (previously presented): The method of claim 136, wherein the biologically active molecules are bound to the valency platform molecule via a linker group such that an oxime bond, or modified form thereof, is formed upon bonding the linker group to the valency platform molecule.

Claim 139 (previously presented): The method of claim 136, wherein the biologically active molecules comprise a carbonyl group of an aldehyde or ketone moiety.

Claim 140 (previously presented): The method of claim 139, wherein the biologically active molecules comprise a polypeptide; and, wherein the method comprises modifying the polypeptide prior to bonding with an aminooxy group on the valency platform molecule, such that the polypeptide comprises a terminal aldehyde group.

Claim 141 (previously presented): The conjugate of claim 67, wherein the conjugate comprises one or more bivalent linker molecules that link a biologically active molecule to the valency platform molecule, such that a linkage bond is formed between the bivalent linker molecule and the valency platform molecule.

Claim 142 (previously presented): The conjugate of claim 67, wherein the biologically active molecule is a polypeptide comprising a terminal glyoxyl group that reacts with the aminooxy group on the valency platform molecule to form, an oxime linkage.

Claim 143 (previously presented): The conjugate of claim 141, wherein the linkage bond is formed by reacting the valency platform molecule with the bivalent linker molecule, wherein the bivalent linker molecule comprises a carbonyl containing functional moiety.

Claim 144 (previously presented): The conjugate of claim 83, wherein the conjugate comprises one or more bivalent linker molecules that link a biologically active molecule to the valency platform molecule, such that a linkage bond is formed between the bivalent linker molecule and the valency platform molecule.

Claim 145 (previously presented): The conjugate of claim 83, wherein the biologically active molecule is a polypeptide comprising a terminal glyoxyl group that reacts with an aminooxy group on the valency platform molecule to form an oxime linkage.

Claim 146 (previously presented): The conjugate of claim 144, wherein the linkage bond is formed by reacting the valency platform molecule with the bivalent linker molecule, wherein the bivalent linker molecule comprises a carbonyl containing functional moiety

Claim 147 (previously presented): A pharmaceutical composition comprising the conjugate of claim 67 and a pharmaceutically acceptable carrier.

Claim 148 (previously presented): A composition comprising two or more valency platform molecules according to claim 66, wherein the valency platform molecules have a polydispersity less than about 1.2.

Claim 149 (previously presented): A pharmaceutical composition comprising the conjugate of claim 83 and a pharmaceutically acceptable carrier.

Claim 150 (previously presented): A composition comprising two or more valency platform molecules according to claim 82, wherein the valency platform molecules have a polydispersity less than about 1.2.

Claim 151 (previously presented): The conjugate of 68, wherein the biologically active molecules comprise a polypeptide.

Claim 152 (previously presented): The conjugate of claim 68, wherein the biologically active molecules comprise a nucleic acid.

Claim 153 (previously presented): The conjugate of claim 68, wherein the biologically active molecules comprise an oligonucleotide.

Claim 154 (previously presented): The conjugate of claim 84, wherein the biologically active molecules comprise a polypeptide.

Claim 155 (previously presented): The conjugate of claim 84, wherein the biologically active molecules comprise a nucleic acid.

Claim 156 (previously presented): The conjugate of claim 84, wherein the biologically active molecules comprise an oligonucleotide.

Claim 157 (previously presented): A pharmaceutical composition comprising the conjugate of claim 55 and a pharmaceutically acceptable carrier.

Claim 158 (previously presented): A pharmaceutical composition comprising the conjugate of claim 56 and a pharmaceutically acceptable carrier.

Claim 159 (previously presented): A pharmaceutical composition comprising the conjugate of claim 69 and a pharmaceutically acceptable carrier.

Claim 160 (previously presented): A pharmaceutical composition comprising the conjugate of claim 70 and a pharmaceutically acceptable carrier.

Claim 161 (previously presented): A pharmaceutical composition comprising the conjugate of claim 85 and a pharmaceutically acceptable carrier.

Claim 162 (previously presented): A pharmaceutical composition comprising the conjugate of claim 86 and a pharmaceutically acceptable carrier.

Claim 163 (previously presented): The conjugate of any of claims 54, 55, 56, 68, 69, 70, 84, 85, or 86, wherein the biologically active molecules interact specifically with proteinaceous receptors.

Claim 164 (previously presented): The conjugate of any of claims 54, 55, 56, 68, 69, 70, 84, 85, or 86, wherein the conjugate is a tolerogen.

Claim 165 (previously presented): The conjugate of any of claims 54, 55, 56, 68, 69, 70, 84, 85, or 86, wherein the conjugate induces specific B cell anergy to an immunogen.

Claim 166 (currently amended): The valency platform molecule of any of claims 38, 66 or 82 ~~53, 67 or 83~~, wherein any one or more aminooxy group (ONH₂) of the valency platform molecule is protected with a Boc protecting group.

Claim 167 (previously presented): An aminooxy protected form of a valency platform molecule according to any of claims 38, 66 or 82.

Claim 168 (previously presented): A valency platform molecule according to any of claims 38, 66 or 82, wherein the amino groups (ONH₂) are unprotected.

Claim 169 (currently amended): A conjugate of any of claims 109, 142 or 145 ~~46, 68 or 83~~ wherein the conjugate comprises a linker that attaches the biologically active molecule to the valency platform molecule.

Claim 170 (previously presented): A composition comprising two or more valency platform molecules according to any of claims 38, 66 or 82 wherein the polydispersity of the valency platform molecules in the composition is between about 1.05 to 1.5.

Claim 171 (previously presented): A composition comprising two or more valency platform molecules according to any of claims 38, 66 or 82 wherein the polydispersity of the valency platform molecules in the composition is between about 1.05 to 1.2.

Claim 172 (previously presented): A composition comprising two or more valency platform molecules according to any of claims 38, 66 or 82 wherein the polydispersity of the valency platform molecules in the composition is less than 1.5.

Claim 173 (previously presented): A composition comprising two or more valency platform molecules according to any of claims 38, 66 or 82 wherein the polydispersity of the valency platform molecules in the composition is less than 1.07.

Claim 174 (previously presented): A composition comprising two or more valency platform molecules according to any of claims 38, 66 or 82 wherein the polydispersity of the valency platform molecules in the composition is less than 1.02.